A recent study shows that a new vaccine can prevent tuberculosis in people with HIV. Phase III trials of 2,000 HIV-infected people in Tanzania found that the mycobacterium vaccae (MV) vaccine reduced the rate of tuberculosis (TB) by 39 percent. The findings have been published in the on line journal called AIIDS. TB is the most common cause of death among patients suffering with HIV. The results of the clinical trials are a significant milestone according to principal investigator Dr. Ford von Reyn, director of the Dar Dar International Programs for the infectious disease and international health section at Dartmouth Medical School, in Hanover, N.H.
The development of a new vaccine against tuberculosis is a major international health priority, especially for patients with HIV infection, The next step involves improving manufacturing methods so that sufficient quantities of the MV vaccine can be produced for further studies and possible use in patients. The researchers are of the view that people newly infected with HIV should be administered with MV vaccine before they begin taking antiretroviral drugs to fight Hiv infection.